SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wells Fargo Maintains Alnylam at Equal-Weight, Cuts Target to $220

Wells Fargo maintained its Equal-Weight rating on Alnylam Pharmaceuticals and lowered its price target to $220 from $253.

ALNY

Related stories